Comparative Pharmacology
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL 10 11 versus NORLUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORETHINDRONE AND ETHINYL ESTRADIOL 10 11 versus NORLUTATE.
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11) vs NORLUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol suppresses follicle-stimulating hormone (FSH) and luteinizing hormone (LH) secretion, inhibiting ovulation; norethindrone alters cervical mucus, endometrial lining, and sperm penetration.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial transformation.
One tablet (norethindrone 0.5 mg/ethinyl estradiol 35 mcg for days 1-10; norethindrone 1 mg/ethinyl estradiol 35 mcg for days 11-21) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
5 mg orally once daily for 5 days, starting on day 1 of menstrual cycle; for menorrhagia, 5 mg orally three times daily from day 19 to day 26 of cycle.
None Documented
None Documented
Norethindrone: terminal half-life ~7-8 hours. Ethinyl estradiol: terminal half-life ~13-27 hours (mean ~17 hours). Clinical context: Steady-state achieved within ~5-10 days; dosing interval based on maintaining contraceptive efficacy.
Terminal elimination half-life is approximately 5-6 hours. Clinical context: supports twice-daily dosing; steady state reached within 2 days.
Norethindrone and ethinyl estradiol are primarily eliminated via renal excretion. Norethindrone is excreted as glucuronide and sulfate conjugates, with ~50% renal and ~20-30% fecal. Ethinyl estradiol is extensively metabolized; ~40% renal and ~60% fecal as conjugates.
Primarily renal (approximately 60% of metabolites, mostly glucuronides), with about 40% fecal/biliary elimination. Less than 1% excreted unchanged.
Category D/X
Category C
Progestin
Progestin